Kinase activity-independent role of EphA2 in the regulation of M-phase progression.


Journal

Experimental cell research
ISSN: 1090-2422
Titre abrégé: Exp Cell Res
Pays: United States
ID NLM: 0373226

Informations de publication

Date de publication:
15 10 2020
Historique:
received: 14 08 2019
revised: 17 07 2020
accepted: 26 07 2020
pubmed: 5 8 2020
medline: 4 3 2021
entrez: 5 8 2020
Statut: ppublish

Résumé

Cell division is a tightly regulated, essential process for cell proliferation. Very recently, we reported that EphA2 is phosphorylated at Ser897, via the Cdk1/MEK/ERK/RSK pathway, during M phase and contributes to proper M-phase progression by maintaining cortical rigidity via the EphA2pSer897/ephexin4/RhoG pathway. Here, we show that EphA2 kinase activity is dispensable for M-phase progression. Although EphA2 knockdown delayed this progression, the delay was rescued by an EphA2 mutant expression with an Asp739 to Asn substitution, as well as by wild-type EphA2. Western blotting analysis confirmed that the Asp739Asn mutant lost its EphA2 kinase activity. Like wild-type EphA2, the Asp739Asn mutant was localized to the plasma membrane irrespective of cell cycle. While RhoG localization to the plasma membrane was decreased in EphA2 knockdown cells, it was rescued by re-expression of wild-type EphA2 but not via the mutant containing the Ser897 to Ala substitution. This confirmed our recent report that phosphorylation at Ser897 is responsible for RhoG localization to the plasma membrane. In agreement with the M-phase progression's rescue effect, the Asp739Asn mutant rescued RhoG localization in EphA2 knockdown cells. These results suggest that EphA2 regulates M-phase progression in a manner independent of its kinase activity.

Identifiants

pubmed: 32750331
pii: S0014-4827(20)30456-0
doi: 10.1016/j.yexcr.2020.112207
pii:
doi:

Substances chimiques

EPHA2 protein, human 0
Ephrin-A2 0
Guanine Nucleotide Exchange Factors 0
Phosphoserine 17885-08-4
Receptor, EphA2 EC 2.7.10.1
CDC2 Protein Kinase EC 2.7.11.22

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112207

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Yuichiro Kaibori (Y)

Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.

Kiriko Katayama (K)

Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.

Yuka Tanaka (Y)

Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.

Masayoshi Ikeuchi (M)

Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.

Mika Ogawa (M)

Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.

Yuki Ikeda (Y)

Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.

Ryuzaburo Yuki (R)

Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.

Youhei Saito (Y)

Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.

Yuji Nakayama (Y)

Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan. Electronic address: nakayama@mb.kyoto-phu.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH